On May 4, 2023 NeuExcell Therapeutics, a gene therapy company focusing on neurodegenerative diseases, reported the company has completed a $15+ million Series Pre-A+ financing round (Press release, NeuExcell Therapeutics, MAY 4, 2023, View Source [SID1234638278]). The investors of this round include Shanghai Zhangjiang Leading Qifan Venture Capital，Jiangxi Jilinxinsheng Enterprise Management, Fujian Haixi Pharmaceuticals, Suzhou Industrial Park Technology Innovation Investment, Suzhou Suxin Junnuo Venture Capital, Guangzhou Huiju Xinxing Equity Investment, Guangdong Jike Achievement Transformation Venture Capital Fund and Quanzhou Hongshi II Venture Capital.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to be recognized by investors during a market of biotech slowdown," stated Dr. Xudong Yin, Chairman of the Board of NeuExcell Therapeutics. "The support of investors will help the company apply its unique in vivo neuroregenerative platform technology to the treatment of a variety of neurodegenerative diseases. The positive response to this financing round reflects the investors’ recognition of the company’s strategy and technological advancement".
"This round of financing will accelerate the transformation of our in situ neural regeneration technology to the clinic and bring effective treatment to tens of millions of patients around the world," said Professor Gong Chen, Founder and Chief Scientific Advisor of the company. "There are urgent needs of breakthrough therapies like ours to reverse neurological deficits caused by neuronal loss."
About NeuExcell Therapeutics
NeuExcell is a privately held biotech company focusing on in vivo neural regeneration and repair using adeno-associated virus (AAV)-based gene therapy. Its mission is to improve the lives of patients suffering from neurodegenerative diseases and CNS injuries. Based upon the scientific work of Prof. Gong Chen, the Company has developed a potentially disruptive neural repair technology platform through in vivo astrocyte-to-neuron conversion mediated by neural transcription factor(s). NeuExcell’s pipeline covers major neurodegenerative diseases such as Stroke, Glioma, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, and Spinal Cord Injury.